Business News • PR NewsWire • Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial

Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial

Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial

THOUSAND OAKS, Calif., Nov. 5, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive data from the first three years of the open-label extension study of the pivotal Phase 3 fracture trial showing that six years of Prolia® (denosumab) treatment in postmenopausal women...

View More : http://www.prnewswire.com/news-releases/prolia-denosumab-open-label-extension-trial-showed-continued-increase-in-bone-mi...

Releted News by prnewswire

Santaris Pharma A/S Phase 2a Data of Miravirsen Shows Dose-Dependent, Prolonged Viral Reduction of 2-3 Logs HCV RNA After Four-Week Treatment in Hepatitis C Patients

Santaris Pharma A/S' Phase 2a forsøg med miravirsen i patienter inficeret med Hepatitis C viser efter fire ugers behandling en dosis-afhængig, langtidsvirkende virus reduktion med 2-3 logs i HCV RNA

Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease

Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial

In the Mood for Great Barbecue? Come to Dickey's Barbecue in Florida

Biochemistry and Bioengineering Research Brings California Students Closer to Nation's Highest Science Honor for High School Students